Loading clinical trials...

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Follow-up of Study C87040: Multicentre, Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 (Certolizumab Pegol) Subcutaneous at 2 Different Dose Regimens (400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks) or Placebo for 12 Weeks, in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy, Having Responded to Treatment in Study C87040 and Having Subsequently Relapsed

NCT00329303•UCB Pharma

View on ClinicalTrials.gov

Summary

The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 \[NCT00245765\] and Week 12 of re-treatment in this study.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subject having responded to treatment at Week 12 in study C87040 and having relapsed during the follow-up period
•Female subjects either postmenopausal for at least one year, surgically incapable of childbearing, or effectively practising an acceptable method of contraception.Subjects agreed to continue using adequate contraception during the study and for 12 weeks after the last dose of CDP870

Exclusion Criteria

•Subjects with erythrodermic, guttate, generalized pustular form of psoriasis
•Any recent serious or life-threatening infection or any current sign or symptom that may indicate an infection (e.g., fever, cough)
•Positive hepatitis B surface antigen test and /or hepatitis C antibody test results
•Positive human immunodeficiency virus (HIV) test result
•White blood cell counts less than 4000 per cubic millimeter or more than 20000 per cubic millimeter
•Suspected or diagnosed demyelinating disease of the central nervous system (e.g. multiple sclerosis or optic neuritis)
•Systemic Lupus Erythematosus
•Participation in a clinical study within the past 3 months except Study C87040
•Any other condition, which in the Investigator's judgment would make the subject unsuitable for inclusion in the study

Locations (14)

Besançon, France

Créteil, France

Nice, France

Paris, France

Pierre-Bénite, France

Berlin, Germany

Bonn, Germany

Essen, Germany

Frankfurt, Germany

Hamburg, Germany

Key Dates

Start Date

April 1, 2006

Primary Completion Date

May 1, 2007

Completion Date

May 1, 2007

Last Updated

May 6, 2019

Enrollment

ACTUAL participants

Conditions

Psoriasis

Interventions

Certolizumab Pegol (Cimzia®)

DRUG

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

NCT07449234

Psoriasis

View study

RECRUITINGPHASE3

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

NCT07116967

Plaque Psoriasis

View study

RECRUITINGPHASE3

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

NCT07250802

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 6, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis

Inclusion Criteria

Exclusion Criteria

A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe Psoriasis

Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)

A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis

An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis

Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis

Real-Life Evaluation of Guselkumab Dosing Interval Adjustments